The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and Safety of Single and Double Doses of Ivermectin versus 7-Day High Dose Albendazole for Chronic Strongyloidiasis
Open accessAbstract
BACKGROUND: Strongyloidiasis, caused by an intestinal helminth Strongyloides stercoralis, is common throughout the tropics. It remains an important health problem due to autoinfection, which may result in hyperinfection and disseminated infection in immunosuppressed patients, especially patients receiving chemotherapy or corticosteroid treatment. Ivermectin and albendazole are effective against strongyloidiasis. However, the efficacy and the most effective dosing regimen are to be determined. METHODS: A prospective, randomized, open study was conducted in which a 7-day course of oral albendazole 800 mg daily was compared with a single dose (200 microgram/kilogram body weight), or double doses, given 2 weeks apart, of ivermectin in Thai patients with chronic strongyloidiasis. Patients were followed-up with 2 weeks after initiation of treatment, then 1 month, 3 months, 6 months, 9 months, and 1 year after treatment. Combination of direct microscopic examination of fecal smear, formol-ether concentration method, and modified Koga agar plate culture were used to detect strongyloides larvae in two consecutive fecal samples in each follow-up visit. The primary endpoint was clearance of strongyloides larvae from feces after treatment and at one year follow-up. RESULTS: Ninety patients were included in the analysis (30, 31 and 29 patients in albendazole, single dose, and double doses ivermectin group, respectively). All except one patient in this study had at least one concomitant disease. Diabetes mellitus, systemic lupus erythrematosus, nephrotic syndrome, hematologic malignancy, solid tumor and human immunodeficiency virus infection were common concomitant diseases in these patients. The median (range) duration of follow-up were 19 (2-76) weeks in albendazole group, 39 (2-74) weeks in single dose ivermectin group, and 26 (2-74) weeks in double doses ivermectin group. Parasitological cure rate were 63.3%, 96.8% and 93.1% in albendazole, single dose oral ivermectin, and double doses of oral ivermectin respectively (P = 0.006) in modified intention to treat analysis. No serious adverse event associated with treatment was found in any of the groups. CONCLUSION/SIGNIFICANCE: This study confirms that both a single, and a double dose of oral ivermectin taken two weeks apart, is more effective than a 7-day course of high dose albendazole for patients with chronic infection due to S. stercoralis. Double dose of ivermectin, taken two weeks apart, might be more effective than a single dose in patients with concomitant illness. TRIAL REGISTRATION: ClinicalTrials.gov NCT00765024.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm
Bethony, J., Brooker, S., Albonico, M., Geiger, S. M., Loukas, A., Diemert, D., & Hotez, P. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68653-4 · Cited by 2,478
Cited by
Mejia, R., & Nutman, T. B. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283551dbd · Cited by 392
Human infection with Strongyloides stercoralis and other related Strongyloides species
NUTMAN, T. B. (2017) · Parasitology · doi:10.1017/s0031182016000834 · Cited by 353
Strongyloides stercoralis: A Plea for Action
Bisoffi, Z., Buonfrate, D., Montresor, A., Requena-Méndez, A., Muñoz, J., Krolewiecki, A. J., Gotuzzo, E., Mena, M. A., Chiodini, P. L., Anselmi, M., et al. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002214 · Cited by 313
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection
Henriquez-Camacho, C., Gotuzzo, E., Echevarria, J., White Jr, A. C., Terashima, A., Samalvides, F., Pérez-Molina, J. A., & Plana, M. N. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007745.pub3 · Cited by 193
Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature
Geri, G., Rabbat, A., Mayaux, J., Zafrani, L., Chalumeau-Lemoine, L., Guidet, B., Azoulay, E., & Pène, F. (2015) · Infection · doi:10.1007/s15010-015-0799-1 · Cited by 118
Metadata
- Authors
- Suputtamongkol, Y., Premasathian, N., Bhumimuang, K., Waywa, D., Nilganuwong, S., Karuphong, E., Anekthananon, T., Wanachiwanawin, D., & Silpasakorn, S.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-05-10
- Volume
- 5
- Issue
- 5
- Pages
- e1044
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W1998711609
- Cited by
- 168
- References
- 1
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.